Literature DB >> 1378788

Management of angina pectoris. Modern concepts.

E Kaplinsky1.   

Abstract

While William Heberden gave us an excellent clinical description of angina pectoris more than 200 years ago, the understanding and management of this disorder have undergone major development since then, and especially so in recent years. The pathological basis for the disease was established shortly after Heberden's account. The concept of the imbalance between supply and demand was postulated in the nineteenth century. Recent progress has been made in mainly three areas: the better definition of prognosis, new insights into pathophysiology, and newer management modalities and aims. Today, the combination of the patient's functional state (exercise test), his heart (ventricular function) and coronary anatomy (angiography) enables us to accurately define the prognosis of the disease. Sophisticated studies have now demonstrated that during an exercise-induced angina attack there is a reduction in coronary blood flow and an increase in coronary resistance. Mechanisms associated with the angina attack involve the sclerotic epicardial arteries and the microcirculation. Further major advances in the medical management of angina pectoris now depend on our ability to improve prognosis and retard the development of the atherosclerotic process.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1378788     DOI: 10.2165/00003495-199200431-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  24 in total

1.  Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II)

Authors: 
Journal:  Am J Cardiol       Date:  1990-10-01       Impact factor: 2.778

Review 2.  Modification of experimental atherosclerosis by calcium-channel blockers.

Authors:  W W Parmley; S Blumlein; R Sievers
Journal:  Am J Cardiol       Date:  1985-01-25       Impact factor: 2.778

3.  Prognostic importance of a clinical profile and exercise test in medically treated patients with coronary artery disease.

Authors:  D A Weiner; T J Ryan; C H McCabe; B R Chaitman; L T Sheffield; J C Ferguson; L D Fisher; F Tristani
Journal:  J Am Coll Cardiol       Date:  1984-03       Impact factor: 24.094

4.  Regional myocardial perfusion and wall thickening during ischemia in conscious dogs.

Authors:  K P Gallagher; M Matsuzaki; J A Koziol; W S Kemper; J Ross
Journal:  Am J Physiol       Date:  1984-11

5.  Reduction of exercise-induced ischemic regional myocardial dysfunction by verapamil in conscious dogs.

Authors:  G Osakada; T Kumada; K P Gallagher; W S Kemper; J Ross
Journal:  Am Heart J       Date:  1981-06       Impact factor: 4.749

6.  Protective effect of pretreatment with verapamil, nifedipine and propranolol on mitochondrial function in the ischemic and reperfused myocardium.

Authors:  W G Nayler; R Ferrari; A Williams
Journal:  Am J Cardiol       Date:  1980-08       Impact factor: 2.778

7.  Survival of medically treated patients in the coronary artery surgery study (CASS) registry.

Authors:  M B Mock; I Ringqvist; L D Fisher; K B Davis; B R Chaitman; N T Kouchoukos; G C Kaiser; E Alderman; T J Ryan; R O Russell; S Mullin; D Fray; T Killip
Journal:  Circulation       Date:  1982-09       Impact factor: 29.690

8.  Effects of verapamil on ischemia-induced changes in extracellular K+, pH, and local activation in the pig.

Authors:  W F Fleet; T A Johnson; C A Graebner; C L Engle; L S Gettes
Journal:  Circulation       Date:  1986-04       Impact factor: 29.690

9.  Effect of exercise on the relationship between myocardial blood flow and systolic wall thickening in dogs with acute coronary stenosis.

Authors:  K P Gallagher; M Matsuzaki; G Osakada; W S Kemper; J Ross
Journal:  Circ Res       Date:  1983-06       Impact factor: 17.367

10.  Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators.

Authors:  P R Lichtlen; P G Hugenholtz; W Rafflenbeul; H Hecker; S Jost; J W Deckers
Journal:  Lancet       Date:  1990-05-12       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.